Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Skye BioscienceFRA:09R -17.43%20 EV-to-EBITDA is -0.03 as of Aug. 10, 2026. GuruFocus rates FRA:09R with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 400 Biotechnology companies, Skye Bioscience ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Skye Bioscience's enterprise value is €1.26 Mil.
Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-48.68 Mil. Therefore, Skye Bioscience's EV-to-EBITDA for today is -0.03.
The historical rank and industry rank for Skye Bioscience's EV-to-EBITDA or its related term are showing as below:
FRA:09R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.03 Med: 0 Max: 0
Current: -0.03
FRA:09R's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs FRA:09R: -0.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Skye Bioscience's PE Ratio (TTM) for today is calculated as:
Skye Bioscience's share price for today is €0.36.
Skye Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.238.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Skye Bioscience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:09R vs ATOS, JSPR, TVRD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Skye Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's EV-to-EBITDA falls into.
Skye Bioscience's current Enterprise Value is €1.26 Mil.
Skye Bioscience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-48.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience (FRA:09R) has a EV-to-EBITDA of -0.03 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Skye Bioscience. According to the industry distribution chart, Skye Bioscience ranks #999999 out of 400 companies in the Biotechnology industry.
Is Skye Bioscience's EV-to-EBITDA too high?
Skye Bioscience's current EV-to-EBITDA is -0.03. Based on the distribution chart, Skye Bioscience ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Skye Bioscience has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's EV-to-EBITDA compare to ATOS and JSPR?
According to the Biotechnology industry distribution chart, Skye Bioscience ranks #999999 out of 400 companies for EV-to-EBITDA. This places Skye Bioscience in the lower half of its industry. The industry median EV-to-EBITDA is 13.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Skye Bioscience. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skye Bioscience's current EV-to-EBITDA is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current EV-to-EBITDA of -0.03. The current EV-to-EBITDA is -0.03. Skye Bioscience's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current EV-to-EBITDA is -0.03 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
20GF Score
Get the complete analysis for FRA:09R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:09R has been successfully added to your 
